Company: STAA
Filing Date: 2025-10-02
Form Type: DFAN14A
Source: 0001213900-25-095514
Chunk: 40

Company: STAAR SURGICAL CO
Filing Date: 2025-10-02
Form: DFAN14A
Chunk 40
---
 plan represented the best path forward and determined not to engage further with Alcon ▪ Now, the Board has concluded that STAAR is only worth $28 per share, even though the Company’s prospects have not changed mea nin gfully The Price Is Well Below Alcon’s Prior Offers 1 2 4 5 6 3 1. See page 75 for further information. 2. See page 47 for further information. 3. Source: FactSet. Data includes all all - cash acquisitions of U.S. public companies announced from January 1, 2015 to September 15 , 2025.

Broadwood Partners, L.P. The Proposed Merger Values STAAR Below Comparable MedTech Companies… 54 1 We believe STAAR warrants a materially higher valuation multiple, based on those of other comparable MedTech companies 1. Source: FactSet. Data as of September 23, 2025. 2. “Comparable MedTech Companies” include Alcon AG, Alphatec Holdings, Inc., AtriCure , Inc., Axogen , Inc., DexCom , Inc., Establishment Labs Holdings, Inc., Glaukos Corp, Insulet Corporation, iRhythm Technologies, Inc., Penumbra, Inc., PROCEPT BioRobotics Corp., TransMedics Group, Inc. Vericel Corporation and Treace Medical Concepts, Inc. Peer data refers to median. See page 75 for further information. 5.0x 4.0x 3.7x 6.0x 4.9x 4.1x CY 2025E CY 2026E CY2027E EV/Revenue Multiple¹ Proposed Merger Comparable MedTech Companies²

Broadwood Partners, L.P. …Below the Company’s Historical Valuation Multiple… 55 2 It appears that Alcon took full advantage of STAAR’s recent – and, in our view, temporary – decline in valuation Source: FactSet. Data as of August 4, 2025, the last trading day before the Proposed Merger was announced. 4.0x 3.7x 5.1x 4.3x 9.6x 7.7x FY+1 FY+2 STAAR EV / Revenue Multiple Proposed Merger 3-Year Average 5-Year Average

Broadwood Partners, L.P. …Below STAAR’s Historical Stock Price… 56 3 The Proposed Merger consideration